Summit downgraded at H.C. Wainwright after Merck data for sac-TMT
Source: SeekingAlpha
2026-05-22 11:46:03 ET
More on Summit Therapeutics, Merck
- A Futuristic Synthesis Indeed
- Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary
- Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
- AbbVie, Merck, Astra among winners of EU drug recommendations this week
- Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial
Read the full article on Seeking Alpha
For further details see:
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT
Akeso
NASDAQ: AKESF
AKESF Trading
-6.92% G/L:
$12.10 Last:
2,287 Volume:
$12.174 Open:
